Sano M, Kushida K, Takahashi M, Ohishi T, Kawana K, Okada M, Inoue T
Department of Orthopaedic Surgery, Hamamatsu University School of Medicine, Japan.
Br J Cancer. 1994 Oct;70(4):701-3. doi: 10.1038/bjc.1994.377.
Bone metastases from prostate carcinoma are predominantly osteoblastic. Recently, urinary pyridinoline (Pyr) and deoxypyridinoline (Dpyr) have been employed as indicators of bone resorption. In this study, we evaluated urinary Pyr and Dpyr levels in 19 prostate carcinoma patients, of whom 12 had bone metastasis and seven had not, and 11 age-matched control subjects. There was a significant difference in Pyr levels between the control group and the patients with metastasis (mean +/- s.d., 19.5 +/- 7.2 vs 73.3 +/- 67.1 nmol mmol-1 creatinine, P < 0.05). The mean level of Dpyr in the patients with metastasis (10.8 +/- 8.0 nmol mmol-1 creatinine) was significantly higher than that in the control group (3.1 +/- 2.1 nmol mmol-1 creatinine, P < 0.01), and also higher than that in the patients without metastasis (3.5 +/- 1.9 nmol mmol-1 creatinine, P < 0.05). There was no significant difference in Pyr and Dpyr levels between the control group and the patients without metastasis. These results suggest that bone resorption is also accelerated in prostate carcinoma patients with bone metastasis.
前列腺癌的骨转移主要为成骨性。近来，尿吡啶啉（Pyr）和脱氧吡啶啉（Dpyr）已被用作骨吸收的指标。在本研究中，我们评估了19例前列腺癌患者的尿Pyr和Dpyr水平，其中12例有骨转移，7例无骨转移，以及11名年龄匹配的对照受试者。对照组与有骨转移患者的Pyr水平存在显著差异（均值±标准差，19.5±7.2对73.3±67.1 nmol mmol⁻¹肌酐，P<0.05）。有骨转移患者的Dpyr平均水平（10.8±8.0 nmol mmol⁻¹肌酐）显著高于对照组（3.1±2.1 nmol mmol⁻¹肌酐，P<0.01），也高于无骨转移患者（3.5±1.9 nmol mmol⁻¹肌酐，P<0.05）。对照组与无骨转移患者的Pyr和Dpyr水平无显著差异。这些结果表明，有骨转移的前列腺癌患者的骨吸收也会加速。
